Expert Review: Atrial Fibrillation, Pharmacotherapy, Thrombosis, Valve Disease

Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease

Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Valvular heart disease (VHD) is associated with a higher incidence of thromboembolic events, regardless of the underlying cardiac rhythm [1]. Atrial fibrillation (AF) is associated with a higher incidence of thromboembolic events in patients with rheumatic mitral stenosis or in patients with nonvalvular AF [2,3]. Warfarin is indicated for prevention of thromboembolic events in patients with mechanical prosthetic heart valves and in patients with AF and mitral stenosis [3-5]. The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban reduced stroke or systemic embolism, caused less bleeding, and decreased mortality in comparison with warfarin [6], and on the basis of this trial, has been approved for prevention of thromboembolic events in patients with nonvalvular AF. The ARISTOTLE trial excluded patients with mechanical prosthetic heart valves and patients with moderate or severe mitral stenosis but included patients with other VHD [6]. Of the 18,201 patients with AF in the ARISTOTLE trial, 4808 patients (26.4%) had a history of moderate or severe other VHD or previous valve surgery. The present study showed that there was no evidence of a different effect of apixaban compared with warfarin in patients with and without VHD in reducing stroke and systemic embolism (hazard ratio =0.70; 95% CI, 0.51-0.97 versus hazard ratio =0.84; 95% CI, 0.67-1.04; interaction p = 0.38), in reducing major bleeding (hazard ratio =0.79; 95% CI, 0.61-1.04; versus hazard ratio = 0.65; 95% CI, 0.55-0.77; interaction p=0.23), and in decreasing mortality (hazard ratio =1.01; 95% CI, 0.84-1.22; versus hazard ratio = 0.84; 95% CI, 0.73-0.96; interaction p=0.10).

 

 

Conclusion

The coexistence of AF and VHD is associated with a higher risk of thromboembolic events and bleeding. There is a lack of available data evaluating direct oral anticoagulants in patients with VHD and AF. The current analysis provides a reliable evaluation of the efficacy and safety of apixaban in patients with VHD. Apixaban, in comparison with warfarin, had similar relative and larger absolute benefits in reducing stroke or systemic embolism, causing less bleeding, and reducing mortality in patients with VHD in comparison with those without VHD. These results will potentially improve the cardiovascular burden of AF in VHD.

 

Corresponding author from original paper

Alvaro Avezum, MD, PhD, Dante Pazzanese

Institute of Cardiology, Av. Dante Pazzanese, 500 04012909 São Paulo, Brazil.

E-mail avezum@dantepazzanese.org.br

 

REFERENCES

  1. Petty GW, Khandheria BK, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO Predictors of cerebrovascular events and death among patients with valvular heart disease: A population-based study. Stroke. 2000; 31(11):2628-35
  2. Wolf PA, Dawber TR, Thomas HE, Kannel WB.Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978; 28(10):973-7
  3. Aronow WS. Management of atrial fibrillation in the elderly. Minerva Med. 2009 ; 100(1):3-24
  4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY, American College of Chest Physicians- Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e531S-75S
  5. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19):2369-429
  6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92

Citation: Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015; 132(8):624-32 .

Leave a Reply

Your email address will not be published.